argenx agreed to buy Dallas‑based Forte for about $2.2 billion, folding Forte’s experimental anti‑CD122 drug FB102 into argenx’s immunology lineup.

A UT Health San Antonio–led analysis finds frontotemporal dementia shows up differently in Hispanic patients — with more movement symptoms and longer diagnostic delays. The authors call for larger, culturally informed studies.

Nvidia’s reported talks to underwrite OpenAI’s Ohio lease would fold a chip supplier into financing for the world’s largest AI campus, reviving circular‑financing concerns.